This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Mayo Clinic Study on Alzheimer's...
Tech medical breakthrough

Mayo Clinic Study on Alzheimer's Progression in Women

Analysis based on 10 articles · First reported Mar 04, 2026 · Last updated Mar 05, 2026

Sentiment
50
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

This medical breakthrough could lead to more targeted drug development and clinical trials for Alzheimer's disease, particularly for women, potentially boosting pharmaceutical and biotechnology companies focused on neurodegenerative diseases. It may also influence investment in personalized medicine approaches.

Pharmaceuticals Biotechnology Healthcare
Event Summary

A Mayo Clinic study, published in JAMA Network Open, revealed that Alzheimer's-related brain changes progressed up to 20 times faster in women who also had abnormal levels of alpha-synuclein, a protein linked to Parkinson's disease. This accelerated progression was not observed in men. The findings suggest that the interaction between alpha-synuclein and Alzheimer's pathology may drive faster disease progression in women, potentially explaining why women constitute nearly two-thirds of Alzheimer's patients in the United States. Kejal Kantarci and Elijah Mak, key researchers from Mayo Clinic, highlighted that these sex-specific differences could lead to more targeted clinical trials and personalized treatment strategies for Alzheimer's disease.

Key Actions
95 Mayo Clinic published study findings JAMA Network Open
85 Kejal Kantarci co-authored significant medical research
80 Elijah Mak authored significant medical research
Entities Involved
ngo
Mayo Clinic
Mayo Clinic researchers published a study in JAMA Network Open, identifying a significant sex-specific difference in Alzheimer's disease progression. This research enhances Mayo Clinic's reputation as a leader in medical research.
Importance 90 Sentiment 20
per
Kejal Kantarci
Kejal Kantarci, a neuroradiologist at Mayo Clinic and senior author of the study, emphasized the importance of recognizing sex-specific differences for targeted clinical trials and personalized treatment strategies.
Importance 85 Sentiment 20
per
Elijah Mak
Elijah Mak, first author of the study and a Mayo Clinic neuroimaging researcher, highlighted that this discovery opens new avenues for understanding why women are disproportionately affected by dementia.
Importance 80 Sentiment 20
priv
JAMA Network Open
JAMA Network Open published the Mayo Clinic study, increasing its visibility and reinforcing its role as a prominent medical journal.
Importance 70 Sentiment 10
ngo
Alzheimer s Disease Neuroimaging Initiative
The Alzheimer s Disease Neuroimaging Initiative, a national research consortium, provided the data from 415 participants that was analyzed in the Mayo Clinic study.
Importance 60 Sentiment 10
cnt
United States
The study's findings are relevant to the United States, where women constitute nearly two-thirds of people living with Alzheimer's disease.
Importance 20 Sentiment 0
Relationships
Kejal Kantarci related ↔ Mayo Clinic
Elijah Mak related ↔ Mayo Clinic
Mayo Clinic related ↔ JAMA Network Open
Kejal Kantarci related ↔ JAMA Network Open
Elijah Mak related ↔ JAMA Network Open
Kejal Kantarci related ↔ Elijah Mak
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.